ImageneBio Inc

NASDAQ:IMA

Biotechnology

Healthcare
$4.61 +6.06%

+$0.35 today

Market cap
$52.00M
Beta
0.72
P/E (TTM)
-1.5
EPS (TTM)
-$4.02
52W Low $3.94High $18.00

Volume 0.00M

Average 0.35M

IMA Common Stock Issued

Cash raised by issuing new shares.

ImageneBio IncNASDAQ: IMA

Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026

Common stock issued turns negative

Q1 FY2026 common stock issued was -$3.24M, compared with $0 a year earlier. Trailing-twelve-month common stock issued was $62.59M.

Context

  • Common stock issued amounted to 8229.6% of revenue in FY2025, up 8229.6 pp from a year earlier.
  • Common stock issued increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock issued holds near -$3.24M or moves back toward the trailing-twelve-month quarterly average of $15.65M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.24M— QoQ
Last fiscal yearDec 2025
$65.84M— YoY
LTMMar 2026
$62.59M— YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
65.84M USD
Year-over-year change
—
4-year CAGR
-15.9%

Common Stock Issued vs competitors

How IMA compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
IMA Competitors
Common Stock Issued for IMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OVIDOvid Therapeutics Inc.LTM Mar 2026$164.18M USD+40238.1%+646.7%2305.2%
STROSutro Biopharma, Inc.LTM Mar 2026$103.37M USD+5.6%-81.2%103.8%
IMAImageneBio IncLTM Mar 2026$62.59M USD———
KLRSKalaris Therapeutics IncLTM Mar 2026$50.07M USD———
STTKShattuck Labs, Inc.LTM Mar 2026$26.22M USD+2495.6%+538.3%2621.6%
IFRXInflaRx N.V.LTM Mar 2026€16.2M EUR-6.0%+139.7%55236.8%
CNTBConnect Biopharma Holdings LimitedFY2025$1.09M USD+381.5%+293.1%1707.8%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$131K USD———
CNTXContext Therapeutics Inc.LTM Mar 2026$0 USD-100.0%-46.9%—
Peer median (excluding IMA) —+193.6%+216.4%2305.2%

Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(34.12M)(68.77M)(68.17M)(49.23M)(52.4M)
Depreciation & Amortization544K751K1.02M490K328K
Deferred Income Tax00000
Stock-Based Compensation5.18M7.53M05.3M15.39M
Change in Working Capital(33.03M)(15.14M)(21.67M)(3.98M)(19.19M)
Accounts Receivables361K(291K)000
Inventory00000
Accounts Payables00(2.87M)(1.17M)(2.82M)
Other Working Capital(33.39M)(14.85M)(18.8M)(2.81M)(16.37M)
Other Non-Cash Items1.17M1.52M9.07M1.42M8.02M
Operating Cash Flow(60.25M)(74.11M)(79.74M)(46M)(47.84M)
Capital Expenditures(1.76M)(1.43M)(414K)00
Acquisitions (Net)0000(5.22M)
Purchases of Investments0(216.34M)(90.05M)(88.3M)(10.4M)
Sales of Investments0118.49M154.61M60.46M9.8M
Other Investing Activities000(7.07M)0
Investing Cash Flow(1.76M)(99.28M)64.14M(34.9M)(5.81M)
Debt Repayment000015M
Common Stock Issued131.3M037.56M065.84M
Common Stock Repurchased00(663K)00
Dividends Paid00000
Other Financing Activities582K1.1M39.09M054.63M
Financing Cash Flow131.74M1.1M75.98M0135.47M
Effect of Forex Changes00(406K)0604K
Net Change in Cash69.73M(172.3M)59.98M(80.91M)82.41M
Free Cash Flow(62.01M)(75.54M)(80.16M)(46M)(47.84M)

ImageneBio Inc

NASDAQ:IMA

Intrinsic Alpha fair value

Locked

Current Price

$4.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.